Literature DB >> 22245252

Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway.

Zhijian Lu1, Na Lu, Chenglin Li, Fanni Li, Kai Zhao, Biqi Lin, Qinglong Guo.   

Abstract

Matrix metalloproteinases (MMPs) play important roles in the invasion and migration of cancer cells. In this study, we used in vitro and in vivo assays to examine the inhibitory effects of oroxylin A, one of the main bioactive flavonoid extracted from Scutellaria radix, on the human breast carcinoma cell MDA-MB-231 invasion and migration. We found that oroxylin A can suppress cell adhesion, invasion and migration in a concentration-dependent manner. Moreover, oroxylin A led to the reduction of the activity and expression levels of MMP-2 and MMP-9 in gelatin zymography, real-time PCR and western blotting analysis. Further elucidation of the mechanism revealed that oroxylin A increased the expression of tissue inhibitor of metalloproteinase-2 (TIMP-2), the endogenous inhibitor of MMP-2, and repressed the phorbol-12-myristate-13-acetate (PMA)-induced translocation of protein kinase Cδ (PKCδ), phosphorylation of extracellular signal-regulated kinase (ERK1/2) and binding activity of the transcription factor activator protein-1 (AP-1) which are upstream signaling molecules in MMP-9 expression. Our results also indicated that oroxylin A inhibited the lung metastasis of murine melanoma cell B16-F10 in vivo. Therefore, we proposed that oroxylin A might be developed as a therapeutic potential candidate for the treatment of cancer metastasis. Copyright Â
© 2012 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22245252     DOI: 10.1016/j.toxlet.2011.12.022

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  18 in total

1.  Clinicopathologic significance of β-catenin and matrix metalloproteinase-2 expression in non-small cell lung cancer.

Authors:  Guang-Hu Li; Yong-Sheng Cui; Qi-Yu Wu; Xiong-Ji Zhang; Yu-Fei Gao
Journal:  Med Oncol       Date:  2013-01-05       Impact factor: 3.064

Review 2.  Progression of cutaneous melanoma: implications for treatment.

Authors:  Stanley P L Leong; Martin C Mihm; George F Murphy; Dave S B Hoon; Mohammed Kashani-Sabet; Sanjiv S Agarwala; Jonathan S Zager; Axel Hauschild; Vernon K Sondak; Valerie Guild; John M Kirkwood
Journal:  Clin Exp Metastasis       Date:  2012-08-15       Impact factor: 5.150

Review 3.  Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives.

Authors:  Hardeep Singh Tuli; Vivek Kumar Garg; Ajay Kumar; Diwakar Aggarwal; Uttpal Anand; Nidarshana Chaturvedi Parashar; Adesh K Saini; Ranjan K Mohapatra; Kuldeep Dhama; Manoj Kumar; Tejveer Singh; Jagjit Kaur; Katrin Sak
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-10-10       Impact factor: 3.195

Review 4.  Perspectives on natural compounds in chemoprevention and treatment of cancer: an update with new promising compounds.

Authors:  Abedul Haque; Daniel Brazeau; Arm R Amin
Journal:  Eur J Cancer       Date:  2021-04-14       Impact factor: 9.162

Review 5.  Extracellular matrix as target for antitumor therapy.

Authors:  Revekka Harisi; Andras Jeney
Journal:  Onco Targets Ther       Date:  2015-06-09       Impact factor: 4.147

6.  Oroxylin a, but not vasopressin, ameliorates cardiac dysfunction of endotoxemic rats.

Authors:  Chin-Hung Liu; Mei-Fang Chen; Tzu-Ling Tseng; Lih-Geeng Chen; Jon-Son Kuo; Tony Jer-Fu Lee
Journal:  Evid Based Complement Alternat Med       Date:  2012-10-24       Impact factor: 2.629

7.  Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma.

Authors:  L Wei; Y Zhou; Q Dai; C Qiao; L Zhao; H Hui; N Lu; Q-L Guo
Journal:  Cell Death Dis       Date:  2013-04-18       Impact factor: 8.469

8.  Non-thermal atmospheric pressure plasma inhibits thyroid papillary cancer cell invasion via cytoskeletal modulation, altered MMP-2/-9/uPA activity.

Authors:  Jae Won Chang; Sung Un Kang; Yoo Seob Shin; Kang Il Kim; Seong Jin Seo; Sang Sik Yang; Jong-Soo Lee; Eunpyo Moon; Keunho Lee; Chul-Ho Kim
Journal:  PLoS One       Date:  2014-03-25       Impact factor: 3.240

9.  Clinicopathologic significance of claudin-6, occludin, and matrix metalloproteinases -2 expression in ovarian carcinoma.

Authors:  Liping Wang; Xiangshu Jin; Dongjing Lin; Zhijing Liu; Xiaowei Zhang; Yan Lu; Yuanyuan Liu; Min Wang; Minlan Yang; Jiuxia Li; Chengshi Quan
Journal:  Diagn Pathol       Date:  2013-11-19       Impact factor: 2.644

10.  Inhibitory effects of oroxylin A on endothelial protein C receptor shedding in vitro and in vivo.

Authors:  Sae-Kwang Ku; Min-Su Han; Min Young Lee; You-Mie Lee; Jong-Sup Bae
Journal:  BMB Rep       Date:  2014-06       Impact factor: 4.778

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.